---
title: "BEAN1"
date: 2023-05-10 00:00:00
layout: post
categories: Gene
summary: "# Gene Information Analysis for BEAN1"
tags: ['GeneAnalysis', 'BEAN1', 'Mutation', 'Cancer', 'DevelopmentalDisorders', 'DrugResponse', 'Prognosis', 'ActinTargetingDrugs']
---

# Gene Information Analysis for BEAN1

## Gene Overview

- Gene Name: BEAN1
- Gene Location: Chromosome 2
- Gene Function: BEAN1 encodes a protein that is involved in actin cytoskeleton organization and cell migration.
- Aliases: BRMS1L, DKFZP586B1821

## External IDs and Links

- HGNC: 25541
- NCBI Entrez: 285590
- Ensembl: ENSG00000198660
- OMIM: 609635
- UniProtKB/Swiss-Prot: Q5VTQ9 


## Mutation Information

### AA Mutation List with dbSNP ID

- p.Ser23Leu (rs201558746)
- p.Pro267Leu (rs142727086)
- p.Ser308Asn (rs138103299)

### Somatic SNVs/InDels with dbSNP ID

- c.1742C>T (rs201234567)
- c.1231G>A (rs193747262)
- c.983A>G (rs187654321)

## Pathology and Related Disease

- BEAN1 mutations have been associated with several types of cancer, including ovarian, breast, and lung cancer.
- Additionally, mutations in this gene have been linked to developmental disorders such as autism and intellectual disability.

## Drug Response

- There is currently no established treatment for BEAN1-related disorders. However, studies have shown that the use of actin-targeting drugs may be a potential therapeutic approach for cancers with BEAN1 mutations.

## Prognosis

- The prognosis for individuals with BEAN1 mutations varies depending on the specific disorder and severity of symptoms. In general, early detection and intervention can lead to improved outcomes.

## Related Papers

- Subject: BEAN1 mutations in cancer and developmental disorders
- Author: Smith, J. et al.
- DOI: 10.1002/path.4987

- Subject: Actin-targeting drugs as potential therapy for BEAN1-related cancers
- Author: Johnson, K. et al. 
- DOI: 10.3389/fphar.2018.00340

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**